Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.
Calluna Pharma ASOct 23 2024 Calluna Pharma AS , a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate. The study demonstrated a favorable safety, pharmacokinetic and immunogenicity profile for the mAb.
CAL101 is a first-in-class mAb that targets S100A4, a damage-associated molecular pattern protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis. Preclinical studies have demonstrated the ability of CAL101 to prevent and treat fibrosis and modify the disease-specific activation of fibroblasts – the key effector cells driving progression of fibrosis.
We are encouraged by the findings from the Phase 1 study. These results are an important step forward in the development of our lead asset, CAL101, particularly for fibrotic and fibro-inflammatory diseases where there remains a critical need for innovative therapeutic options. We are excited as we now move into the next phase of clinical development.
Biotechnology Fibrosis Placebo Protein
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the BoardCalluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.
Read more »
Pharma 4.0: Shaping the Future of Pharmaceutical ManufacturingThe evolution of Pharma 4.0 integrates advanced technologies, transforming drug development and manufacturing with improved efficiency and product quality.
Read more »
New combination treatment authorized for unresectable urothelial cancer patientsAstellas Pharma Ltd.
Read more »
How to streamline supply chain logistics for optimal pharma deliveryLearn how to streamline supply chain logistics in the pharmaceutical industry for optimal delivery. Discover strategies here.
Read more »
Alzheimer’s ‘wonder drug’ was approved by scientists funded by pharma firmA BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab received direct payments from drug companies
Read more »
Details of latest phase of 600-home scheme is tabledDevelopment will take shape on site of former gas works
Read more »